Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


President Signs FDA User Fee Legislation


 
Sen. Lamar Alexander

On Aug. 18, President Donald Trump signed bipartisan legislation authored by Senate health committee Chairman Lamar Alexander (R-Tenn.) and Ranking Member Patty Murray (D-Wash.) intended to speed safe drugs and medical devices into patients' medicine cabinets and doctors' offices, while maintaining safety and effectiveness standards.

"The legislation signed by the president today will speed the FDA's work to review new cures and treatments and get them into patients' medicine cabinets and doctors' offices," Alexander said after the legislation was signed. "The first step was last year's passage of 21st Century Cures to spur medical research, and this is the next step -- legislation to help ensure that these breakthroughs in research make it to patients."

"I'm pleased that Democrats and Republicans in Congress were able to set aside partisanship, work together to put patients and families first, and ensure the FDA continues to have the resources it needs to advance safe, effective medical products for people across the country," Murray said. "This legislation reflects years of hard work by the Obama Administration, as well as members on both sides of the aisle, and I want to express my appreciation in particular to Chairman Alexander for his leadership. I hope we can build on this step forward with additional efforts to strengthen healthcare for the communities we all serve."

The legislation was passed by the Senate on Aug. 3 by a vote of 94-1.

The legislation includes four different user fee agreements that must be reauthorized by Sept. 30. The bill is virtually identical to legislation overwhelmingly approved by the Senate's health committee on May 11. This legislation will reauthorize the authority for the Food and Drug Administration (FDA) to accept user fees - paid by manufacturers of drugs and medical devices - that account for $8 to $9 billion over 5 years and is over a quarter of all FDA funding. The reauthorizations are based on recommendations from industry and FDA after a public process.

Over the last two years, the HELP Committee led by Alexander and Murray has held 15 bipartisan briefings, including some with the House Energy and Commerce Committee, to hear from FDA and industry about the reauthorization. The HELP Committee held two bipartisan hearings, on March 21 and April 4, on the medical device and drug user fees. The committee held a markup on the bill on May 11, when two bipartisan amendments were adopted, and the committee overwhelmingly approved the bill -- voting 21 to 2.

 
Share:

Related Articles:


Recent Articles

Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Read More

DRUG COMPANIES URGED TO PROVIDE DISCOUNTS TO 340B COMMUNITY PHARMACIES

Yesterday, counsel for the American Hospital Association and the five other national groups and three individual hospital systems that sued the Department of Health and Human Services (HHS) over its failure to halt drug company actions that undermine the 340B drug pricing program sent letters demanding that the offending drug companies immediately halt their illegal activities.

Read More

Study Shows Drastic Increases in Opioid-Affected Births

The rate of mothers who had an opioid-related diagnosis when delivering their baby increased by 131% from 2010-2017, as the incidence of babies diagnosed with drug withdrawal, known as neonatal abstinence syndrome (NAS), increased by 82% nationally during that same time period.

Read More

Case Management: Enhancing Revenue, Care Transitions and Patient Outcomes throughout the Hospital System

The importance of hospital and health system case management has grown exponentially over the past 10 years and is now getting attention from leaders throughout the healthcare industry.

Read More

TennCare Block Grant Waiver Approved

More than a year after submitting Amendment 42 to the Centers for Medicare and Medicaid Services (CMS) requesting a waiver to increase flexibility in the administration of the state's Medicaid program, Tennessee has received an affirmative nod to move forward.

Read More

OptumInsight and Change Healthcare Combine to Advance a More Modern, Information and Technology-Enabled Health Care Platform

Accelerates work to improve outcomes and experiences and lower the cost of health care

Read More

AHA Statement On Dc Circuit Court Of Appeals Decision On Mandated Disclosure Of Negotiated Rates

Read More

AHA STATEMENT ON COURT DELAY OF MOST FAVORED NATION MODEL INTERIM FINAL RULE

Read More

Sen. Alexander's Farewell Address

Read More

Alexander: Congress Set to End Surprise Medical Billing

Proposal to protect patients from surprise medical bills and resolve payment disputes between providers and insurers included in government funding legislation that the Congress will vote on this week

Read More

Email Print
 
 

 

 


Tags:
FDA, Food & Drug Administration, HELP Committee, Lamar Alexander, Patty Murray, U.S. Senate
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: